The Great Benefits Purge: Why Corporate America is Firing Its Pharmacy Advisors

BIRMINGHAM, Ala. – October 12, 2026 – For decades, the relationship between corporate employers and their employee benefits advisors was characterized by a quiet, comfortable inertia. Contracts auto-renewed, pharmacy benefit managers (PBMs) quietly processed claims, and year-over-year cost increases were accepted as an unavoidable reality of doing business.

That era is violently over.

According to a new market report released today by RxBenefits, a staggering 75% of employers have either fired their pharmacy benefits advisor in the past 12 months or plan to do so in the next year. Even more alarming for the healthcare establishment: 87% of employers state they are likely to switch their PBM at their next contract renewal.

The report, titled "2026 State of Pharmacy Benefits Decisions: The Churn Trap," draws on proprietary survey data collected by FTI Consulting from 601 employers and 300 benefits advisors. As someone who has tracked the intersection of healthcare economics and corporate strategy for years, I view these numbers not as a cyclical market correction, but as a structural collapse of trust.

The vendor arrangements that once anchored pharmacy decisions are losing their hold. Driven by a confluence of aggressive new federal regulations, the looming threat of fiduciary litigation, and the budget-breaking reality of next-generation weight-loss drugs, corporate America is demanding a fundamental rewrite of the pharmacy benefits playbook.

The Benefits Broker Reckoning

To understand why three-quarters of employers are severing ties with their advisors, one must look at the legal tightrope self-insured plan sponsors are now walking.

The catalyst was the Consolidated Appropriations Act (CAA) of 2021, specifically Section 202, which mandated unprecedented disclosure requirements for broker compensation. For the first time, brokers and consultants were legally required to disclose all direct and indirect compensation they received from third parties, including PBMs and insurance carriers.

This regulatory sunlight exposed a labyrinth of hidden fees, indirect commissions, and misaligned incentives. Employers suddenly realized that the advisors they trusted to negotiate the lowest possible drug costs were often being compensated by the very PBMs they were supposed to be evaluating.

Compounding this realization is the terrifying new reality of ERISA fiduciary litigation. Recent high-profile lawsuits—most notably the class action against Johnson & Johnson regarding its employee benefits plan—have sent shockwaves through corporate boardrooms. Employers are legally bound fiduciaries under ERISA, meaning they are personally liable if they fail to prudently manage plan assets and monitor service providers.

As one healthcare ERISA attorney noted recently, corporate executives are waking up to the fact that pleading ignorance about complex PBM contracts is no longer a viable legal defense. Advisors who cannot provide clear, documented proof that their compensation and vendor recommendations align strictly with the employer's financial interests are being swiftly replaced. Trust has been replaced by the demand for auditable accountability.

The Death of 'Transparent' Marketing

For the past five years, the PBM industry's primary defense against criticism has been the buzzword of "transparency." Upstart PBMs and legacy giants alike rebranded their services, promising pass-through pricing and an end to the controversial practice of spread pricing—where a PBM charges a health plan more for a drug than it reimburses the pharmacy, pocketing the difference.

But the data reveals a cynical market that has moved past marketing labels. When nearly every provider claims to be transparent, the label ceases to be a differentiator.

Employers are no longer buying the "transparent PBM" narrative at face value. They have realized that a transparently bad deal is still a bad deal. Instead of settling for promises of pass-through rebates, corporate purchasers are now asking much harder questions about plan economics. They are demanding ironclad performance guarantees, verifiable clinical results, and independent rebate audits.

The line between transparent and traditional PBMs has blurred to the point of irrelevance. With 87% of employers willing to endure the massive administrative headache of switching PBMs, it is clear that merely disclosing fees is insufficient. Employers want proof that their PBM is actively driving down the net cost of healthcare, not just transparently reporting on its exponential growth.

The GLP-1 Litmus Test

If fiduciary pressure is the underlying structural shift, the explosion of GLP-1 medications is the immediate financial catalyst driving the current market churn.

With total net drug spend nationwide now exceeding a staggering $600 billion, employers are desperate for clinical trend management. The surging demand for GLP-1 drugs like Wegovy and Zepbound—used for diabetes and weight loss—has broken the traditional benefits budget. Recent industry data indicates that health benefit costs are projected to rise by 6.7% in 2026, the highest spike in 15 years, driven largely by specialty pharmacy and GLP-1 utilization.

Traditional PBM utilization management controls, such as basic prior authorizations and step therapy, have proven woefully inadequate against the overwhelming consumer demand for these medications. Employers are finding that generic PBM approaches simply rubber-stamp expensive prescriptions, draining plan reserves.

Consequently, GLP-1 strategy has emerged as a standalone litmus test for provider readiness. Employers now treat GLP-1 trend management as its own distinct evaluation criterion. They expect a highly defined, clinically rigorous approach to coverage controls, lifestyle program integration, and step therapy enforcement. PBMs and advisors who lack a proactive, specialized strategy for GLP-1s are being viewed as actively negligent and are losing contracts as a result.

Optimization Over Endless Churn

The central thesis of the new market report is that while the sector is defined by switching, another vendor swap rarely solves the underlying systemic problems. Firing an opaque PBM only to hire a "transparent" PBM with weak clinical oversight simply resets the clock on failure.

"Employers are stuck in a churn trap, and another vendor swap won't break it," said Kyra Hagan, senior vice president of marketing and communications at RxBenefits. "What ends the cycle is proof, not promises. Advisors and employers who can point to documented savings, performance guarantees, and real clinical results give their clients a credible reason to stop switching and start optimizing."

This is driving the rise of alternative models, such as the Pharmacy Benefits Optimizer (PBO). Firms utilizing this model operate on a flat-fee basis and position themselves as independent clinical and financial overlays. Rather than acting as a traditional PBM, a PBO aggregates purchasing power, aggressively negotiates PBM contracts, and provides independent clinical oversight that is structurally separated from the dispensing and rebate revenue conflicts that plague traditional managers.

Whether the PBO model becomes the new industry standard remains to be seen. However, the data is unequivocal: the era of passive benefits management is dead. In a landscape defined by $600 billion in drug spend, crippling GLP-1 costs, and the looming threat of fiduciary lawsuits, corporate leaders are demanding active, measurable optimization. Those in the pharmacy benefits ecosystem who cannot provide quantifiable, independent proof of value will find themselves on the wrong side of the greatest vendor purge in modern healthcare history.